There was a significant interaction with hormone receptor status: women who had ER-positive but PgR-negative tumours were likely to have a superior outcome with anastrozole, whereas women with tumours that were positive for both receptors did just as well with tamoxifen as with anastrozole. This evidence concerns the gene NR4A1 and neoplasm.